Your session is about to expire
← Back to Search
Meaningful Activity Plan for Dementia
N/A
Recruiting
Led By Natalie G Regier, PhD
Research Sponsored by Johns Hopkins University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Persons with dementia must be English-speaking
Be older than 18 years old
Must not have
Persons with dementia who are bed-bounded, defined as confined to bed or chair for at least 22 hours a day for at least four of the previous seven days
Persons who are taking any neuroleptic medications or have any of the following medical diagnoses: (a) restless legs syndrome, (b) delirium, or (c) akathisia, medication-induced, or other movement disorders such as Parkinson's disease or essential tremor.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 12 months
Awards & highlights
Summary
This trial focuses on helping those with early-stage dementia by providing them with tailored activity plans.
Who is the study for?
This trial is for English-speaking individuals with an early-stage dementia diagnosis, as per DSM-5 criteria. They must be medically stable and not bed-bound or in palliative care. Participants should have been on a consistent medication dose for at least 60 days if they're taking certain drugs.
What is being tested?
The study tests a user-led activity plan tailored for people with early-stage dementia. It aims to provide meaningful activities that can adapt as the disease progresses, with direct input from the participants themselves.
What are the potential side effects?
Since this intervention involves non-medical activities, traditional side effects like those seen with medications are not expected. However, there may be emotional or psychological responses to new activities which will be closely monitored.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have dementia and I speak English.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have dementia and have been mostly bed-bound for the last week.
Select...
I am not on neuroleptic medications and do not have restless legs, delirium, akathisia, Parkinson's, or essential tremor.
Select...
My dementia is in the moderate or severe stage.
Select...
My dementia is likely due to a head injury.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 12 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in Premorbid cognitive function as assessed by the Wechsler Test of Adult Reading
Change in global cognitive function as assessed by the Wechsler Memory Scale-III
Change in the cognitive domain of attention as assessed by the Wechsler Adult Intelligence Scale
+19 moreSecondary outcome measures
Anxiety
Change in Depression as assessed by the Geriatric Depression Scale
Change in Sense of control as assessed by the Sense of Control Scale
+3 moreTrial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: ExperimentalExperimental Treatment1 Intervention
After participants are recruited, participants will undergo neuropsychological testing prior to randomization in order to establish baseline cognitive functioning and verify that the participants are indeed in the early stages of dementia. Persons randomized to the User-Led Meaningful Activity intervention group will begin the treatment protocol right after randomization. The intervention will consist of 3-4 sessions lasting 60-90 minutes each in which participants receive feedback from the neuropsychological assessment, identify the basis/topic of the activity plan, receive dementia psychoeducation, and map out an activity gradation plan. A brief cognitive screening tool will be re-administered at six months and 12 months. The neuropsychological battery that was administered at baseline will be re-administered 12 months later. Follow-up will also involve solicitation of feedback from the person with dementia and his or her caregiver regarding participants' participation in the study.
Group II: Wait-List ControlActive Control1 Intervention
After participants are recruited, participants will undergo neuropsychological testing prior to randomization in order to establish baseline cognitive functioning and verify that the participants are indeed in the early stages of dementia (i.e., "mild" dementia). Those who meet criteria will be randomly assigned. Persons randomized to the wait-list control group will begin the treatment protocol after four months' time.
Find a Location
Who is running the clinical trial?
National Institute on Aging (NIA)NIH
1,704 Previous Clinical Trials
28,033,187 Total Patients Enrolled
278 Trials studying Dementia
23,628,793 Patients Enrolled for Dementia
Johns Hopkins UniversityLead Sponsor
2,285 Previous Clinical Trials
14,842,995 Total Patients Enrolled
31 Trials studying Dementia
82,459 Patients Enrolled for Dementia
Natalie G Regier, PhDPrincipal InvestigatorJohns Hopkins School of Nursing
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have dementia and have been mostly bed-bound for the last week.I am not on neuroleptic medications and do not have restless legs, delirium, akathisia, Parkinson's, or essential tremor.I have dementia, am alert, and have been on stable medication for 60 days.My dementia is in the moderate or severe stage.My dementia is likely due to a head injury.I have dementia and I speak English.
Research Study Groups:
This trial has the following groups:- Group 1: Experimental
- Group 2: Wait-List Control
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger